MECHANISM OF ACTION
Tesamorelin is a synthetic 44-amino acid GHRH analogue that retains the complete sequence of human GHRH 1-44 with a trans-3-hexenoic acid moiety at the N-terminus for improved stability. Like native GHRH, it binds pituitary GHRH receptors to stimulate pulsatile GH secretion. Unlike CJC-1295 (no DAC), tesamorelin has a shorter half-life (~30–40 min) and is administered daily. The clinical evidence base is strong - FDA approval for HIV-associated lipodystrophy makes it one of the few GHRH analogues with regulatory approval and robust phase III trial data.
RESEARCH APPLICATIONS
- Visceral fat reduction (FDA-approved indication: HIV lipodystrophy)
- GH secretagogue research - pulsatile GH modelling
- Cognitive function in MCI and Alzheimer models (tesamorelin CNS research)
- Body composition recomposition stacks (Shredded stack)
- IGF-1 normalisation in GH-deficient models
RESEARCH HIGHLIGHTS
FDA Approval for Visceral Fat
2007Phase III trials demonstrated 15% reduction in visceral adipose tissue (VAT) by CT scan in HIV patients on stable ART at 26 weeks, leading to FDA approval (Egrifta, 2010).
Ref: Falutz et al., NEJM
Cognitive Benefits in MCI
2021Phase II RCT in adults with MCI: tesamorelin improved cognitive composite scores (verbal memory, executive function) vs. placebo at 20 weeks, proposing IGF-1-mediated neuroprotection.
Ref: Baker et al., J Alzheimers Dis
RESEARCH PROTOCOL NOTES
Chemical Identity
Storage & Stability
Lyophilised: 2–8°C; do not freeze. Reconstituted: use within 3 hours (no preservative in approved formulation). Research multi-dose vials: 2–8°C, 28 days.
Regulatory Status
FDA approved (Egrifta/Egrifta SV) for HIV lipodystrophy only. SA: unscheduled research compound — not a registered medicine under SAHPRA. Supplied for research and laboratory use only. WADA prohibited (S2).